Pegcantratinib

Pegcantratinib (CT327) is a potent and selective TRKA antagonist with activity against TRKB and TRKC. Pegcantratinib can be used for research of CYLD cutaneous syndrome (CCS) and inflammatory dermatoses, such as psoriasis and concomitant pruritus[1].

1233363-33-1

CT327; SNA-120

12352100

Trk Receptor

Neuronal Signaling; Protein Tyrosine Kinase/RTK

Cancer-Kinase/protease

Cancer; Inflammation/Immunology

O=C(N(CCOCCCOCC)C(O1)=O)[C@@]21[C@](C)(O3)N(C4=CC=CC=C45)C6=C5C7=C(C(NC7)=O)C8=C6N([C@H]3C2)C9=CC=CC=C98.[n]

(C2H4O) nC30H24N4O6

[1]Danilenko M, et al. Targeting Tropomyosin Receptor Kinase in Cutaneous CYLD Defective Tumors With Pegcantratinib: The TRAC Randomized Clinical Trial. JAMA Dermatol. 2018 Aug 1;154 (8) :913-921.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-19704/

Reference compound1

No Development Reported

TrkA